AbbVie agreed to pay Chinese biotech Haisco $30 million upfront for two non-opioid acute pain candidates, part of a deal described at up to $745 million. The transaction expands AbbVie’s pain pipeline through candidates positioned against opioid-alternative targets. The update signals continued global partnership activity for mid-to-late preclinical assets, with Chinese biotechs supplying early-stage drug candidates and larger partners underwriting later development and commercialization costs. Market attention will center on the program candidates, development milestones, and how AbbVie structures regional rights across China and other territories.